Simpson Thacher is representing Blackstone and its portfolio company, Precision Medicine Group, in connection with the announced acquisition of Precision Medicine Group by McKesson Corporation for approximately $2.25 billion. The transaction is subject to customary closing conditions, including regulatory clearances.
Precision Medicine Group supports next-generation approaches to drug development and commercialization. Life sciences innovators in biotechnology and pharmaceutical companies rely on Precision Medicine Group to move their discoveries from molecule to market with a breadth of integrated services and technology-enabled products, including biomarker intelligence, lab services, a global clinical research organization, market access consulting and commercialization support.
The Simpson Thacher team includes Elizabeth Cooper, Michael Chao, Erica Egenes, Brian Saleeby and Ramon Callis (M&A); Jonathan Goldstein, Sophie Staples and Roberto Arza (Tax); Gregory Grogan, Laura Gallo and Matias Botto (Executive Compensation & Employee Benefits); Caroline Geiger, Kim Le, Stanley Yu and Anthony Tran (Intellectual Property); Vanessa Burrows, Jacob Madden and Rebecca Rose (Healthcare); Krista McManus and Tim Gallagher (Real Estate); Peter Guryan, Richard Jamgochian and Conner Dwinell (Antitrust); and Steven DeLott (Insurance).